Intravitreal Brolucizumab(玻璃体内布罗卢珠单抗)研究综述
Intravitreal Brolucizumab 玻璃体内布罗卢珠单抗 - The patient was shifted to intravitreal Brolucizumab. [1] Interventions: A combination therapy involving of intravitreal brolucizumab and STTA Outcomes: The anti-vascular endothelial growth factor inhibitor was changed back to aflibercept; however, exudation persisted. [2] Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). [3] Although the serous retinal detachment (SRD) disappeared after IVA treatment, the patient was managed with treatment every 4 weeks without extending the treatment interval To shorten the treatment interval, intravitreal brolucizumab (IVBr) was started 44 weeks after starting IVA treatment. [4]患者被转移到玻璃体内 Brolucizumab。 [1] 干预：玻璃体内溴卢珠单抗和 STTA 联合治疗 结果：抗血管内皮生长因子抑制剂改回阿柏西普；然而，渗出物持续存在。 [2] 患者接受 3 个月的玻璃体内阿柏西普（n = 38）或玻璃体内溴卢珠单抗（n = 14）。 [3] 尽管 IVA 治疗后浆液性视网膜脱离 (SRD) 消失，但患者每 4 周进行一次治疗，不延长治疗间隔。 [4]
neovascular age related 新生血管年龄相关
Case 2: An 82-year-old man who had neovascular age-related macular degeneration, received the first dose of intravitreal brolucizumab injection OD. [1] We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). [2] The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. [3] Purpose To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions. [4] The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. [5]病例2：一名患有新生血管性年龄相关性黄斑变性的82岁男性，接受了第一剂玻璃体内溴卢珠单抗注射液OD。 [1] 我们评估了玻璃体腔内 brolucizumab 加载期治疗新生血管性年龄相关性黄斑变性 (nAMD) 伴 1 型脉络膜新生血管 (CNV) 的疗效和安全性。 [2] 本研究的目的是确定玻璃体内 brolucizumab 治疗在现实环境中治疗新生血管性年龄相关性黄斑变性 (AMD) 的疗效和安全性。 [3] 目的 评估真实条件下印度眼新生血管性年龄相关性黄斑变性 (nAMD) 玻璃体腔内注射 brolucizumab 的短期疗效和安全性。 [4] 本研究旨在确定在现实环境中无负荷剂量的情况下，pro renata (PRN) 玻璃体内溴卢珠单抗治疗新生血管性年龄相关性黄斑变性 (AMD) 的疗效和安全性。 [5]
Received Intravitreal Brolucizumab 接受玻璃体内注射 Brolucizumab
All patients received intravitreal brolucizumab as primary or switch therapy. [1] The woman with a known medical history of an allergy to tropicamide ophthalmic solution, received intravitreal brolucizumab injection for polypoidal choroidal vasculopathy OD. [2]所有患者均接受玻璃体内溴卢珠单抗作为主要或转换治疗。 [1] 已知对托吡卡胺滴眼液过敏病史的女性接受玻璃体内注射溴鲁珠单抗治疗息肉状脉络膜血管病变 OD。 [2]
intravitreal brolucizumab injection 玻璃体内 Brolucizumab 注射液
Case 2: An 82-year-old man who had neovascular age-related macular degeneration, received the first dose of intravitreal brolucizumab injection OD. [1] Purpose To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions. [2] Recently, she had been switched to intravitreal brolucizumab injection. [3] To describe three Japanese cases of retinal vasculitis that occurred following intravitreal brolucizumab injections and the systemic and local steroid treatment administered. [4] The woman with a known medical history of an allergy to tropicamide ophthalmic solution, received intravitreal brolucizumab injection for polypoidal choroidal vasculopathy OD. [5]病例2：一名患有新生血管性年龄相关性黄斑变性的82岁男性，接受了第一剂玻璃体内溴卢珠单抗注射液OD。 [1] 目的 评估真实条件下印度眼新生血管性年龄相关性黄斑变性 (nAMD) 玻璃体腔内注射 brolucizumab 的短期疗效和安全性。 [2] 最近，她已改用玻璃体内溴卢珠单抗注射液。 [3] nan [4] 已知对托吡卡胺滴眼液过敏病史的女性接受玻璃体内注射溴鲁珠单抗治疗息肉状脉络膜血管病变 OD。 [5]
intravitreal brolucizumab therapy 玻璃体内 Brolucizumab 治疗
The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. [1] The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. [2]本研究的目的是确定玻璃体内 brolucizumab 治疗在现实环境中治疗新生血管性年龄相关性黄斑变性 (AMD) 的疗效和安全性。 [1] 本研究旨在确定在现实环境中无负荷剂量的情况下，pro renata (PRN) 玻璃体内溴卢珠单抗治疗新生血管性年龄相关性黄斑变性 (AMD) 的疗效和安全性。 [2]